文献速递神经肌肉病神经免疫

多灶性获得性脱髓鞘性感觉运动神经病的纯运动起病与IgM丙种球蛋白病

Pure Motor Onset and IgM-Gammopathy Occurrence in Multifocal Acquired Demyelinating Sensory and Motor Neuropathy.
PubMed 文献 · Neurology · 2021-10-04

该回顾性研究纳入76例MADSAM患者,发现纯运动起病最常见(53%),其中位感觉受累时间为18个月;25%存在MGUS(89%为IgM型),与神经节苷脂抗体相关;长期免疫治疗反应率75%,MGUS患者更常需双药治疗。

要点

  • MADSAM纯运动起病常见,感觉受累中位时间18个月,需长期随访鉴别MMN。
  • MGUS见于25%的MADSAM患者,多为IgM型,与神经节苷脂抗体相关。
  • 75%患者长期免疫治疗有效,MGUS患者更常需双药联合治疗。

核心结论

  • 纯运动起病是MADSAM最常见的起病形式。
  • 长期随访、重复电生理和神经病理有助于区分纯运动起病MADSAM与MMN。
  • 合并MGUS的MADSAM患者更常需要双药免疫治疗。

主要发现

  • 76例MADSAM中,纯运动起病占53%,纯感觉起病占16%,感觉运动起病占30%,颅神经起病占1%。
  • 纯运动起病患者中位感觉受累时间(经电生理证实)为18个月(范围6-180个月)。
  • MGUS见于25%的患者,其中89%为IgM亚型,与神经节苷脂自身抗体相关(p < 0.001)及更高IgM滴度相关(p < 0.04)。
  • 臂丛和腰骶丛MRI异常率分别为87%(34/39)和84%(21/25),表现为神经增粗和T2信号增高。
  • 近端神经束活检(n=9)较远端活检(n=17)更常显示洋葱球样病理(p = 0.001)和神经内膜炎症(p = 0.01)。

关键数值与推荐

  • MGUS患者初始INCAT残疾评分高于无MGUS患者(p = 0.02)。
  • 长期治疗反应(INCAT评分降低≥1分或mNIS降低>8分)见于75%(49/65)的患者,与MGUS或运动起病无关。
  • 86%的患者需要持续免疫治疗。
  • MGUS患者更常需要双药免疫治疗以达到稳定(p = 0.02)。

临床怎么用

  • 对纯运动起病的神经病患者应长期随访并重复电生理检查,以鉴别MADSAM与MMN。
  • MADSAM患者应筛查单克隆丙种球蛋白和神经节苷脂抗体。
  • 合并MGUS的MADSAM患者可能需要更积极的联合免疫治疗。

局限性

  • 回顾性研究设计。
  • 样本量有限(76例),部分亚组分析样本量小。
  • 研究来自单中心(Mayo Clinic)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To longitudinally investigate patients with multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), quantifying timing and location of sensory involvements in motor onset patients, along with clinicohistopathologic and electrophysiologic findings to ascertain differences in patients with and without monoclonal gammopathy of uncertain significance (MGUS). METHODS: Patients with MADSAM seen at Mayo Clinic and tested for monoclonal gammopathy and ganglioside antibodies were retrospectively reviewed (January 1, 2007-December 31, 2018). RESULTS: Of 76 patients with MADSAM, 53% had pure motor, 16% pure sensory, 30% sensorimotor, and 1% cranial nerve onsets. Motor-onset patients were initially diagnosed with multifocal motor neuropathy (MMN). MGUS occurred in 25% (89% immunoglobulin M [IgM] subtype), associating with ganglioside autoantibodies (p < 0.001) and higher IgM titers (p < 0.04). Median time to sensory involvements (confirmed by electrophysiology) in motor onset patients was 18 months (range 6-180). Compared to initial motor nerve involvements, subsequent sensory findings were within the same territory in 35% (14/40), outside in 20% (8/40), or both in 45% (18/40). Brachial and lumbosacral plexus MRI was abnormal in 87% (34/39) and 84% (21/25), respectively, identifying hypertrophy and increased T2 signal predominantly in brachial plexus trunks (64%), divisions (69%), and cords (69%), and intrapelvic sciatic (64%) and femoral (44%) nerves. Proximal fascicular nerve biopsies (n = 9) more frequently demonstrated onion-bulb pathology (p = 0.001) and endoneurial inflammation (p = 0.01) than distal biopsies (n = 17). MRI and biopsy findings were similar among patient subgroups. Initial Inflammatory Neuropathy Cause and Treatment (INCAT) disability scores were higher in patients with MGUS relative to without (p = 0.02). Long-term treatment responsiveness by INCAT score reduction ≥1 or motor Neuropathy Impairment Score (mNIS) >8-point reduction occurred in 75% (49/65) irrespective of MGUS or motor onsets. Most required ongoing immunotherapy (86%). Patients with MGUS more commonly required dual-agent immunotherapy for stability (p = 0.02). DISCUSSION: Pure motor onsets are the most common MADSAM presentation. Long-term follow-up, repeat electrophysiology, and nerve pathology help distinguish motor onset MADSAM from MMN. Better long-term immunotherapy responsiveness occurs in motor onset MADSAM compared to MMN reports. Patients with MGUS commonly require dual immunotherapy. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that most clinical, electrophysiologic, and histopathologic findings were similar between patients with MADSAM with and without MGUS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Beecher G, Shelly S, Dyck PJB, et al. Pure Motor Onset and IgM-Gammopathy Occurrence in Multifocal Acquired Demyelinating Sensory and Motor Neuropathy. Neurology. 2021. PMID: 34376509. doi:10.1212/WNL.0000000000012618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。